



Aurobindo Pharma receives approvals for Cefprozil Tablets and PFOS from Health Canada

16th April 2010

Aurobindo Pharma Limited is pleased to announce that it has received the approvals for its Abbreviated New Drug Submission for Cefprozil Tablets 250 mg & 500 mg and Cefprozil Powder for Oral Suspension (PFOS) 125 mg/5ml & 250 mg/5 ml from Health Canada

Cefprozil is the generic equivalent of Canadian reference product Cefzil® of Bristol-Myers Squibb Canada Inc and falls under the antibiotic therapeutic category.

With these approvals Aurobindo now has 11 products approved by Health Canada.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com